check drug test results quest diagnostics

CHECK DRUG TEST RESULTS QUEST DIAGNOSTICS PLUS

The marketing materials that NID distributed regarding the Advantage Intact PTH Assay described that product as having 'excellent correlation' to the IRMA Assay. As alleged in the information, there were periods of time in which the Advantage Intact PTH Assay provided elevated results. The criminal resolution focuses solely on the Advantage Intact PTH Assay. Cantor will share in the proceeds of the False Claims Act recovery and will receive approximately $45 million. The United States commenced its civil and criminal investigation after the filing of a qui tam or whistleblower suit brought by Thomas Cantor. The company has also entered into a Corporate Integrity Agreement with the Office of Inspector General of the U.S. Quest has agreed to pay various state Medicaid programs approximately $6.2 million to resolve similar civil claims.

CHECK DRUG TEST RESULTS QUEST DIAGNOSTICS PLUS

Quest has also entered into a non-prosecution agreement with the United States.Īs part of the civil settlement, Quest and NID will pay the United States $262 million plus interest to resolve False Claims Act allegations relating to the Advantage Intact PTH assay and four other assays manufactured by NID that allegedly provided inaccurate and unreliable results. As part of the plea, NID will pay a criminal fine of $40 million. in Brooklyn to a felony misbranding charge in violation of the Food, Drug and Cosmetic Act relating to NID’s Nichols Advantage Chemiluminescence Intact Parathyroid Hormone Immunoassay, a test that was used by laboratories throughout the country to measure parathyroid hormone (PTH) levels in patients. The payment of $302 million will resolve these allegations and represents one of the largest recoveries ever in a case involving a medical device.Īs part of the criminal resolution, NID pleaded guilty today before U.S. Vast clinical drug monitoring resources-from comprehensive reporting and drug monitoring testing guides to Health Trends® reports, an annual study delivering groundbreaking insights on drug misuse in the United States.WASHINGTON – Quest Diagnostics Incorporated and its subsidiary, Nichols Institute Diagnostics (NID), have entered into a global settlement with the United States to resolve criminal and civil claims concerning various types of diagnostic test kits that NID manufactured, marketed and sold to laboratories throughout the country until 2006, the Justice Department announced today.Quarterly usage and positivity reports on a national, regional, and provider level that can help you manage your program.Hospital trend reporting that benchmarks your population’s prescription compliance against local, regional, and national trends.

Data analysis and insights to guide patient care, population health management, and public policy.

Flexible and scalable inpatient and outpatient tests to meet the needs of your system.

Results for all substances are delivered in 1 report, so you can take action quickly to optimize patient care

Definitive drug testing panels, including the most commonly ordered substances.

We’re helping health systems identify and combat drug misuse via: Whether you’re looking to start a clinical drug monitoring program or to supplement your existing program with additional testing services, we collaborate with you to bring the answers, services, and support you need to make a difference in your patients’ lives.

Check drug test results quest diagnostics